Loading
A phase 3 trial of Trifluridine/tipiracil in colorectal cancer, run by Jiangsu Simcere Pharmaceutical Co., Ltd., now recruiting.
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT07361003 by Jiangsu Simcere Pharmaceutical Co., Ltd., with 464 participants planned, started 2025-11-12 and due to reach its primary completion in 2028-01. Interventions recorded: Suvemcitug injection, trifluridine/tipiracil tablets, Suvemcitug placebo injection, trifluridine/tipiracil tablets. Conditions listed: Refractory Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Trifluridine/tipiracil, Cytotoxic chemotherapy, Colorectal cancer.
Shares Trifluridine/tipiracil, Cytotoxic chemotherapy, Colorectal cancer.
Shares Trifluridine/tipiracil, Cytotoxic chemotherapy, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/